• In a bid to deepen healthcare reforms and improve health infrastructure, China increased in healthcare subsidies by 19 percent
• National Development and Reforms Commission removed the price controls on most pharmaceuticals to reduce government intervention and enhance opportunities
• Plans to use competitive bidding for large-scale purchases of certain drugs as a way to guide market pricing and reduce costs of essential drugs
• Chinese government cracked down on rampant bribery by pharmaceutical companies that inflated drug prices
• Wuxi Biologics began construction of a new $150 million biologics manufacturing facility in China as the world's largest mammalian cell culture manufacturing facility
• China aims to implement digital databases for electronic health records and patient information for the entire population by 2020
• Announced to double the number of its general doctors by 2020, trim its public sector and improve technology to fix healthcare system
• An experimental Ebola vaccine candidate developed by the Beijing Institute of Biotechnology and the Tianjin CanSino Biotechnology successfully cleared phase I clinical trials
